The Food and Drug Administration (FDA) has issued a sources sought notice to conduct market research for a potential enterprise-wide Blanket Purchase Agreement (BPA) supporting its Cybersecurity Program. While this is not a solicitation, the draft Statement of Work outlines a broad consolidation of cybersecurity engineering, operations, identity services, AI-enabled capabilities, and post-quantum cryptography into a single acquisition vehicle. This is an early opportunity for small businesses to evaluate future positioning and help shape the agency’s acquisition strategy.
The draft requirements describe an enterprise cybersecurity effort intended to support FDA’s Office of Digital Transformation through an integrated approach spanning cybersecurity engineering, cybersecurity operations and threat management, Identity, Credential, and Access Management (ICAM), Artificial Intelligence and Automation, and Post Quantum Cryptography (PQC). The BPA would establish a consolidated vehicle for delivering these capabilities across FDA’s hybrid enterprise environment.
The engineering scope centers on modernizing cybersecurity platforms across on-premises and cloud environments while aligning with federal cybersecurity guidance. The agency is seeking support for security architecture, platform engineering, cloud security, Zero Trust implementation, SIEM engineering, secure cloud connectivity, cybersecurity modernization, vulnerability management, and integration of enterprise security technologies. AI-enabled compliance monitoring, automated control validation, and continuous authorization capabilities are also included throughout the engineering requirements.
Operational support extends across 24x7x365 Security Operations Center (SOC) and Network Operations Center (NOC) services, endpoint and network security, incident response, digital forensics support, continuous monitoring, threat hunting, vulnerability management, and enterprise security operations. The draft SOW also calls for automation, orchestration, and AI-assisted workflows intended to improve detection, response, and operational efficiency while supporting FDA’s Zero Trust objectives.
Identity services represent another major component of the planned effort. The agency is seeking comprehensive ICAM engineering and operations covering identity governance, privileged access management, multifactor authentication, single sign-on, PKI, certificate management, identity lifecycle management, and support for a centralized Zero Trust Identity Hub. The draft SOW also includes enterprise AI and automation requirements, along with support for preparing FDA’s transition to post-quantum cryptography.
This notice is likely to be of interest to cybersecurity firms, Zero Trust and ICAM providers, cloud security integrators, AI-enabled cybersecurity companies, SOC operators, systems integrators, and firms supporting federal cybersecurity modernization. Small businesses with experience delivering enterprise cybersecurity engineering, operations, AI-enabled security capabilities, and identity services within federal environments should closely monitor this opportunity as FDA refines its acquisition approach.
Read more here. SS-75F40126Q00333
